名称 | PF-562271 besylate |
描述 | PF-562271 besylate (PF-00562271 Besylate) is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. |
细胞实验 | Cells are plated for 48 hours before addition of PF-562271. After 3 days cells are fixed by addition of ice cold 25% trichloroacetic acid (TCA) solution prior to staining with Sulforhodamine B (SRB) dye solution. Plates are washed with 1% glacial acetic acid, air-dried and resuspended in 10 mM Tris buffer, pH 10.5 before reading absorbance at 540 nm. Curve fitting and generation of IC50 values is carried out using GraphPad Prism 4 software from six replicates.(Only for Reference) |
激酶实验 | Recombinant kinase assay and enzyme kinetics : Briefly, purified-activated FAK kinase domain (amino acid 410–689) is reacted with 50 μM ATP and 10 μg per well of a random peptide polymer of Glu and Tyr, p(Glu/Tyr), in kinase buffer [50 mM HEPES (pH 7.5), 125 mM NaCl, and 48 mM MgCl2] for 15 minutes. Phosphorylation of p(Glu/Tyr) is challenged with serially diluted PF-562271 at 1/2-Log concentrations starting at a top concentration of 1 μM. Each concentration is tested in triplicate. Phosphorylation of p(Glu/Tyr) is detected with a general antiphospho-tyrosine (PY20) antibody followed by horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibody. HRP substrate is added, and absorbance readings at 450 nm are obtained after addition of stop solution (2 M H2SO4). IC50 values are determined using the Hill-Slope Model. Broad kinase selectivity profiling is performed in house and by using the KinaseProfiler Selectivity Screening Service available through UpState Biotechnology. |
体外活性 | PF-562271对FAK和Pyk2酪氨酸激酶活性表现出选择性抑制效果,其IC50分别为1.5 nM和14 nM。在基于细胞的实验中,PF-562271对FAK的IC50表现为5 nM,与其他激酶靶标相比表现出更高的选择性。[1] 在二维(2D)培养条件下,PF-562271能够依剂量依赖性抑制FAK WT、FAK/和FAK激酶缺陷(KD)细胞的增殖,其IC50分别为3.3 μM、2.08 μM和2.01 μM。[2] |
体内活性 | 在多个人类皮下移植模型中,PF-562271显示出剂量依赖性的肿瘤生长抑制作用,对PC-3M、BT474、BxPc3和LoVo的最大肿瘤抑制率在每日两次,每次25至50 mg/kg剂量下,范围从78%至94%,且无体重下降、病态或死亡现象。[1] PF-562271(通过p.o.给药,25 mg/kg)在皮下和骨转移的PC3M-luc-C6移植模型中显著减缓了肿瘤进展。[3] 在Huh7.5肝细胞癌移植模型中,sunitinib和PF-562271的联合治疗针对血管生成和肿瘤侵袭性,比单一化合物治疗产生更显著的抗肿瘤效果,通过阻断肿瘤生长及影响肿瘤在撤销治疗后的恢复能力。[4] |
存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 55 mg/mL (82.62 mM), Sonication is recommended.
|
关键字 | PF-562271 besylate | Pyk2 | Inhibitor | FAK | Focal adhesion kinase | inhibit | PF562271 besylate | PF 562271 besylate | VS-6062 besylate | PTK2 | Proline-rich tyrosine kinase 2 | PTK2 protein tyrosine kinase 2 |
相关产品 | Sodium Oxamate | Ribociclib | Palbociclib monohydrochloride | Abemaciclib methanesulfonate | CASIN | Olomoucine | Palbociclib | GW 441756 | Dinaciclib | Defactinib | Ro-3306 | Abemaciclib |
相关库 | 抑制剂库 | 经典已知活性库 | 抗癌活性化合物库 | 已知活性化合物库 | 激酶抑制剂库 | 抗衰老化合物库 | 酪氨酸激酶分子库 | 药物功能重定位化合物库 | 抗癌临床化合物库 | 抗癌药物库 |